-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immunotherapy provides a second-line option for patients with metastatic urothelial carcinoma (mUC) who have failed standard treatment, but biomarkers that predict the response of mUC patients to immunotherapy remain to be explored
This study aims to evaluate the safety, efficacy and related biomarkers of toripalimab in mUC patients who have previously received treatment
The recruited mUC patients received torepalizumab 3 mg/kg Q2W treatment
Overall survival rate of the intention-to-treat population
Overall survival rate of the intention-to-treat populationIn the intention-to-treat population (n=151)
Progression-free survival rate of PD-L1 positive or negative patients
Progression-free survival rate of PD-L1 positive or negative patientsThe objective response rate of patients with PD-L1 positive and high TMB value (≥10 mutations/Mb) was significantly higher than that of PD-L1 negative patients (42% vs 17%; p=0.
The objective response rate of patients with PD-L1 positive and high TMB value (≥10 mutations/Mb) was significantly higher than that of PD-L1 negative patients (42% vs 17%; p=0.
Progression-free productivity in patients with high and low TMB values
Progression-free productivity in patients with high and low TMB valuesAll in all, the results of the study show that torepalizumab as a second-line therapy for patients with metastatic urothelial cancer who failed the first-line treatment has shown encouraging clinical activity and controllable safety
Patients with metastatic urothelial cancer Torre Pali monoclonal antibody used as first-line treatment failure of second-line therapy demonstrated a promising clinical activity, and has a controllable safety Torre Pali monoclonal antibody used as first-line treatment failure The second-line therapy for patients with metastatic urothelial cancer has shown encouraging clinical activity and has controllable safety
Original source:
Original source:Sheng Xinan,Chen Haige,Hu Bin et al.
Leave a message here
